Cargando...
Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV
Author(s)
University of Minnesota
Sarah Samorodnitsky
University of Minnesota
Chris H. Wendt
University of Minnesota
Jason V. Baker
University of Minnesota
Gary Collins
University of Minnesota
Monica Kruk
University of Minnesota
Eric F. Lock
University of Minnesota
Roger Paredes
Selvamuthu Poongulali
Voluntary Health Services Hospital
Danielle O. Weise
University of Minnesota
Alan Winston
St Mary's Hospital
Robin Wood
Ken M. Kunisaki
University of Minnesota
INSIGHT START Pulmonary Substudy Group
University of Copenhagen
Bitten Aagaard
University of Copenhagen
Paul Jansson
University of Copenhagen
Mary Pearson
University of Copenhagen
Abdel G. Babiker
University College London
Alejandro Arenas‐Pinto
Nafisah B Atako
University College London
Edward A. Dennis
University College London
S. Forcat
University College London
Fleur Hudson
University College London
B. Jackson
University College London
Daphne Maas
University College London
Caitlin G. Purvis
University College London
C. T. Russell
UNSW Sydney
Sean Emery
UNSW Sydney
Cara Donahue Carey
UNSW Sydney
Megan Clewett
UNSW Sydney
Simone Jacoby
UNSW Sydney
Fred M. Gordin
Washington DC VA Medical Center
Michael J. Vjecha
Washington DC VA Medical Center
Alejandro Sanchez
Washington DC VA Medical Center
Guido Ruggero Loria
Fundacion Ibis Para la Investigacion de HIV/SIDA
Marcela Doldán
Fundacion Ibis Para la Investigacion de HIV/SIDA
André de Moricz
University Hospital Frankfurt
K. Tillmann
University Hospital Frankfurt
V Müller
National and Kapodistrian University of Athens
Giota Touloumi
National and Kapodistrian University of Athens
Vicky Gioukari
National and Kapodistrian University of Athens
Olga Anagnostou
National and Kapodistrian University of Athens
Pablo Herrero
Patricia López
Anchalee Avihingsanon
HIV Netherlands Australia Thailand Research Collaboration
Patsamon Rerksirikul
HIV Netherlands Australia Thailand Research Collaboration
Site Investigators by Country and institution
Eliana Loiza
Verónica Mingrone
Sofia Lupo
F Marconi
D. Daniel
Royal Perth Hospital
Ana Crinejo
Royal Perth Hospital
Martyn A. French
Royal Perth Hospital
L. Barba
Royal Perth Hospital
Diane Rowling
Holdsworth House Medical Practice
E. Warzywoda
Holdsworth House Medical Practice
Mark Bloch
Westmead Hospital
Swati Agrawal
Westmead Hospital
Dominic E. Dwyer
Westmead Hospital
Bruce Taylor
Westmead Hospital
Lida van Petersen
Centre Hospitalier Universitaire de Saint-Pierre
Luc Mertens
Centre Hospitalier Universitaire de Saint-Pierre
S De Wit
Fundacion Arriarán
K. Kabamba
Fundacion Arriarán
Marcelo Wolff
Helsinki University Hospital
G Allendes
Helsinki University Hospital
Matti Ristola
Helsinki University Hospital
O. Debham
Helsinki University Hospital
Henrik Jessen
University of Würzburg
Arne Jessen
University of Würzburg
S. Wiebecke
University of Cologne
Hartwig Klinker
University of Cologne
Gerd Fätkenheuer
University of Cologne
Clara Lehmann
University of Cologne
I. Knaevelsrud
M. Rittweger
Albrecht Stöhr
Klinikum Dortmund
Karl S. Oláh
Klinikum Dortmund
Bernhard Schaaf
Universitätsklinikum Erlangen
Martin Hower
Universitätsklinikum Erlangen
Thomas Harrer
Universitätsklinikum Erlangen
Ellen G. Harrer
Universitätsklinikum Erlangen
A. Skoutelis
AHEPA University Hospital
Vasilios Papastamopoulos
AHEPA University Hospital
Simeon Metallidis
AHEPA University Hospital
Οlga Tsachouridou
AHEPA University Hospital
Sanjay Pujari
Voluntary Health Services Hospital
Abhishek Chitalikar
Voluntary Health Services Hospital
N. Kumarasamy
Rambam Health Care Campus
Faith Esther Beulah
Rambam Health Care Campus
Eduardo Shahar
Tel Aviv Sourasky Medical Center
Eynat Kedem
Rambam Health Care Campus
Dan Turner
Tel Aviv Sourasky Medical Center
Juan Sierra Madero
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Carlos Madrigal
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Kamal Marhoum El Filali
Institute of Human Virology
I. Erradey
Institute of Human Virology
Ernest Ekong
Asociación Civil Impacta Salud y Educación
Nnakelu Eriobu
Asociación Civil Impacta Salud y Educación
Javier Valencia
Manuel Garza-León
Esmelda Montalbán
Raúl Salazar
Jesús Vega
M. del Portal
Fernando Mendo
Elżbieta Bąkowska
Anna Ignatowska
Marcin Czarnecki
Aleksandra Szymczak
Robin Wood
M. Rattley
S. Pillay
Rosie Mngqibisa
Thoko Ndaba
Paradise Madlala
Vicente Estrada
M.E. Rodrigo
M. Gutierrez
José Muñóz
David Dalmau
Cristina Badía
Bonaventura Clotet
Josep M. Llibre
Kiat Ruxrungtham
Sivaporn Gatechompol
Sasisopin Kiertiburanakul
Nutaporn Sanmeema
Chureeratana Bowonwatanuwong
U. Ampunpong
Wisit Prasithsirikul
Supeda Thongyen
Ploenchan Chetchotisakd
Siriluck Anunnatsiri
Winai Ratanasuwan
Peerawong Werarak
Cissy Kityo
H. Mugerwa
Paula Munderi
Joseph Lutaakome
Amanda Clarke
Andrew Bexley
Sayantan Das
Amandip Sahota
C R Emerson
Shannon McKernan
Margaret Johnson
M Youle
Jonathan Ross
J. W. Harding
Stephen Kegg
Tarik Moussaoui
Fangfang Chen
Sharonann Lynch
Andrew De Burgh-Thomas
W. A. I. P. Karunaratne
David H. Dockrell
C. Bowman
Alan Winston
Borja Mora‐Peris
David Chadwick
Peter Lambert
Neeraj Desai
W. Carter
Keith Henry
R. Givot
M. Chow
B. Holloway
Stephen E. Weis
I. Vecino
Richard M. Novak
Gabriel J. Culbert
Aimee Wilkin
Libyadda J. Mosley
Nathan M. Thielman
J. Granholm
Victoria Watson
C. Clark
Joary Vargas Santana
I. Boneta
Indira Brar
Linda Makohon
Rodger D. MacArthur
Marti J. Farrough
M. Frank
Sarah J. Parker
Ellen Tedaldi
Mayra C. Santiago
Susan L. Koletar
Heather Harber
D. Thomas
Ioana Bica
Benjamin Adams
C. VAN DAM
Michael A. Kolber
Karen Moreno
Amanda Brown
B Wade
Date Issued
23 de marzo de 2023
Type
Article
Volume
13
Issue
1
Series/Report No.
Scientific Reports
Start Page
4749
End Page
4749
ISSN
2045-2322
Abstract
Abstract Chronic obstructive pulmonary disease (COPD) is among the leading causes of death worldwide and HIV is an independent risk factor for the development of COPD. However, the etiology of this increased risk and means to identify persons with HIV (PWH) at highest risk for COPD have remained elusive. Biomarkers may reveal etiologic pathways and allow better COPD risk stratification. We performed a matched case:control study of PWH in the Strategic Timing of Antiretoviral Treatment (START) pulmonary substudy. Cases had rapid lung function decline (> 40 mL/year FEV 1 decline) and controls had stable lung function (+ 20 to − 20 mL/year). The analysis was performed in two distinct groups: (1) those who were virally suppressed for at least 6 months and (2) those with untreated HIV (from the START deferred treatment arm). We used linear mixed effects models to test the relationship between case:control status and blood concentrations of pneumoproteins (surfactant protein-D and club cell secretory protein), and biomarkers of inflammation (IL-6 and hsCRP) and coagulation (d-dimer and fibrinogen); concentrations were measured within ± 6 months of first included spirometry. We included an interaction with treatment group (untreated HIV vs viral suppression) to test if associations varied by treatment group. This analysis included 77 matched case:control pairs in the virally suppressed batch, and 42 matched case:control pairs in the untreated HIV batch (n = 238 total) who were followed for a median of 3 years. Median (IQR) CD4 + count was lowest in the controls with untreated HIV at 674 (580, 838). We found no significant associations between case:control status and pneumoprotein or biomarker concentrations in either virally suppressed or untreated PWH. In this cohort of relatively young, recently diagnosed PWH, concentrations of pneumoproteins and biomarkers of inflammation and coagulation were not associated with subsequent rapid lung function decline. Trial registration: NCT00867048 and NCT01797367.
Keywords